UCB Media Room: ASBMR 2022

https://mb.cision.com/Public/18595/3626810/bfb7641196362f41_800x800ar.png ** ASBMR 2022: 3D modelling of hip DXA scans in postmenopausal women with o= steoporosis reveals superior improvements in bone density of romosozumab ve= rsus controls ------------------------------------------------------------ =C2=B7 Post-hoc analyses of the FRAME, ARCH and the STRUCTURE phase 3 trial= s using 3D modelling techniques showed significant cortical and trabecular = bone improvements during the first year in romosozumab-treated patients. =C2=B7 Romosozumab-treated patients achieved greater increases in cortical = volumetric BMD (CvBMD), cortical thickness (Cth), cortical surface BMD (CsB= MD) and trabecular volumetric BMD (TvBMD) than comparator groups, from as e= arly as Month 6 through to Month 12.=C2=A0 =C2=B7 Data further demonstrated that patients at high risk of fracture may= benefit the most from treatment with romosozumab first, followed by an ant= iresorptive.=C2=A0 =C2=B7 Additional data offered new insights into neurological factors contr= ibuting to fracture risk, the impact of the COVID pandemic and subsequent p= ublic health lockdowns on the existing treatment and care gaps, and the use= of artificial intelligence in osteoporosis screening.=C2=A0 Brussels (Belgium), 9 September 2022 =E2=80=93 07:00 (CEST) =E2=80=93 UCB a= nd Amgen, global biopharmaceutical companies, today presented abstracts of = three post-hoc analyses focusing on 3D modelling techniques that highlight = significant cortical and trabecular bone improvements in patients treated w= ith romosozumab. The data were presented along with additional 17 abstracts= , at the American Society for Bone and Mineral Research (ASBMR) 2022 Annual= Congress, taking place from 9th =E2=80=93 12th September in Austin, Texas,= USA.=C2=A0 DXA-based modelling enables estimation of cortical and trabecular bone para= meters comparable to QCT measurements and generates outputs to visualize an= d monitor osteoporosis (OP) treatment. =C2=A0In both analyses, Lewiecki et = al. used DXA-based modelling of the hip to assess 3D bone changes and map t= he distribution of changes in bone parameters over time in patients from FR= AME, ARCH and STRUCTURE.^1 In the first abstract, Lewiecki et al. looked at 3D modelling from hip DXA = scans in postmenopausal women with osteoporosis who received oral bisphosph= onate therapy for =E2=89=A53 years and ALN for =E2=89=A51 year prior to scr= eening, and were randomized to ROMO or a comparator (STRUCTURE: teriparatid= e [TPTD]) for 12 months. The analysis found greater increases in CvBMD, Cth= , CsBMD and TvBMD from as early as Month 6 following treatment with ROMO vs= TPTD, with additional gains observed through to Month 12. The results also= showed TPTD treatment led to a loss in CvBMD, Cth and CsBMD.^2=C2=A0 Another abstract by Lewiecki et al. reported the results of a post-hoc anal= ysis from the FRAME and ARCH studies. Postmenopausal women with osteoporosi= s were randomized to romosozumab 210 mg monthly (ROMO) or a comparator (FRA= ME: PBO; ARCH: alendronate [ALN] 70 mg) for 12 months. After 12 months, all= patients received denosumab (DMAB) in FRAME or ALN in ARCH. 3D modelling f= rom hip DXA scans found that at Month 12, treatment with ROMO vs PBO in FRA= ME and ROMO vs ALN in ARCH resulted in greater increases in cortical volume= tric bone mineral density (CvBMD), cortical thickness (Cth), cortical surfa= ce BMD (CsBMD) and trabecular volumetric BMD (TvBMD). At month 24, the cumu= lative gains in CvBMD, Cth, CsBMD and TvBMD were greater in the ROMO/DMAB v= s PBO/DMAB sequence (P<0.001) and in the ROMO/ALN vs ALN/ALN sequence (P<0.= 05).^1 This data further corroborates the Cosman et al. and McClung et al. = studies that showed greater BMD gains, reduced new vertebral fracture incid= ence and lower incidence of clinical, non-vertebral and hip fractures with = ROMO/DMAB treatment, and significant improved bone microarchitecture with R= OMO/ALN treatment, respectively.^3,4 =C2=A0 Osteoporosis is the most common chronic metabolic bone disease.^5 Character= ised by compromised bone strength, the condition causes approximately 9 mil= lion fractures each year.^5,6 Fragility fractures can result in significant= burden on a person=E2=80=99s life, often making everyday activities such a= s eating, dressing, shopping or driving difficult.^7 =E2=80=9CAs people are living longer, the burden of fragility fractures due= to osteoporosis requires effective addressing. So we are proud to communic= ate additional data supporting romosozumab as a bone forming option for pos= tmenopausal women with severe osteoporosis at high risk of fracture,=E2=80= =9D said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions = & Head of US, UCB. =E2=80=9CASBMR 2022 provides an integral forum for clini= cians and scientists around the world to come together and share the latest= breakthroughs and innovations and so we at UCB are proud to be participati= ng with a wealth of scientific research this year. Our goal is to ensure os= teoporosis care is a priority now and in the future, so we can continue to = improve patient outcomes.=E2=80=9D=C2=A0 During ASBMR 2022, UCB and Amgen showcased their commitment to the screenin= g, treatment, and management of osteoporosis with the presentation of a tot= al of 19 abstracts.=C2=A0 UCB & Amgen abstracts: =C2=B7 One Year of Romosozumab Followed by One Year of Denosumab Compared W= ith Two Years of Denosumab: BMD and Fracture Results From the FRAME and FRA= ME Extension Studies. F. Cosman, M. Oates, D. Betah, S. Ferrari, J. Timosha= nko, Z. Wang, M. McClung=C2=A0 =C2=B7 Trends in Osteoporosis Care Patterns during the COVID-19 Pandemic in= Alberta, Canada. D.L. Kendler, J.P. Brown, A.G. Juby, P. Schneider, R. Wan= i, M. Packalen, S. Avcil, S. Li, M.S. Farris, E. Graves, S. McMullen, T. Ol= iveira=C2=A0 =C2=B7 Current trends in osteoporosis epidemiology and the widening treatme= nt gap among commercially-insured postmenopausal women in the United States= (US). M. Kim, P. Samai, M. Phelan, M. McDermott, C. Deignan, T. Lin, M.A. = Brookhart =C2=B7 Cortical and trabecular bone improvements with romosozumab followed = by denosumab or alendronate assessed using 3D modeling from DXA images. E.M= . Lewiecki, D. Betah, L. Humbert, C. Libanati, M. Oates, Y. Shi, R. Winzenr= ieth, S. Ferrari, F. Omura =C2=B7 Comparison of romosozumab and teriparatide effects on cortical and t= rabecular bone using 3D modeling from DXA images in postmenopausal women tr= ansitioning from bisphosphonate therapy. E.M. Lewiecki, D. Betah, L. Humber= t, C. Libanati, M. Oates, Y. Shi, R. Winzenrieth, S. Ferrari, F. Omura =C2=B7 Clinical Characteristics, Including History of Myocardial Infarction= and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and O= ther Antiosteoporosis Therapies. T. Lin, Y. Liu, T. Arora, M. Oates, C. Dei= gnan, Z. Yu, J.R. Curtis=C2=A0 =C2=B7 Effect of Romosozumab on Bone Microarchitecture as Assessed by Tissu= e Thickness=E2=80=93Adjusted Trabecular Bone Score in Postmenopausal Women = with Osteoporosis: Results from the ARCH Study. M.R. McClung, D. Betah, B.Z= . Leder, D.L. Kendler, M. Oates, J. Timoshanko, Z. Wang =C2=B7 Romosozumab Efficacy in Postmenopausal Women Without Prior Fracture = Who Fulfill AACE Criteria for Osteoanabolic Therapy: Post-Hoc Analysis of C= linical Trial Data. M. McClung, D. Betah, C. Deignan, Y. Shi, J. Timoshanko= , F. Cosman=C2=A0 =C2=B7 Crystal Bone: Validation of a Novel AI/ML Algorithm in the Optum Rel= iant dataset to Identify Patients at Risk of Osteoporotic Fracture in the N= ext 2 Years. E. Mody, R. Yood, C. Deignan, T. Rosenflanz, P. Zhang, T. Kell= ey, N. Payne, C. Andersen=C2=A0 =C2=B7 Crystal Bone: Validation of a Novel AI/ML Algorithm in the Stanford = Health Care dataset to Identify Patients at Risk of Osteoporotic Fracture i= n the Next 2 Years. D.E. Sellmeyer, C. Deignan, T. Rosenflanz, Y. Nazarenko= , P. Zhang, C. Andersen=C2=A0 =C2=B7 One- and five-year survival after fragility fracture: Real-world ret= rospective matched-cohort study in Ontario, Canada. G. Vincent, J.D. Adachi= , E. Schemitsch, J. Tarride, M. Luen, R.J. Wani, J.P. Brown =C2=B7 The Impact of Osteoporotic Fractures on Activities of Daily Living a= nd the Indirect Economic Measures in Five Countries. E. Yeh, O. Rajkovic-Ho= oley, M. Silvey, W.S. Ambler, R. Pinedo-Villanueva, N. Harvey, A. Moayyeri= =C2=A0 Research Collaboration abstracts supported by UCB and Amgen:=C2=A0 =C2=B7 Gradients of risk of clinical risk factors for hip and vertebral fra= cture depend on age and are typically larger at younger age. K. Engelke, C.= C. Gl=C3=BCer, M. Kistler, F. Thomasius, P. Hadji, B. Schweikert, C. Libana= ti, A. Moayyeri=C2=A0 =C2=B7 Retrospective Standalone Performance Testing of a Machine Learning A= lgorithm for Opportunistically Detecting Vertebral Fractures on Chest and A= bdomen CT images in a Chinese population. J. Nicolaes, Y. Liu, P. Huang, Y.= Zhao, L. Wang, A. Yu, J. Dunkel, C. Libanati, X. Cheng=C2=A0 =C2=B7 Evaluation of Romosozumab=E2=80=99s Effects on Bone Marrow Adiposity= in Postmenopausal Osteoporotic Women: Results from The FRAME Bone Biopsy S= ub-Study. P. Chavassieux, J.P. Roux, C. Libanati, Y Shi, R. Chapurlat=C2=A0 =C2=B7 Neurological Clinical Risk Factors For Fracture =E2=80=93 an underap= preciated domain: ICD Code-Based Analysis of a German Health Insurance Data= base. F. Thomasius, K. Engelke, P. Hadji, M. Kistler, B. Schweikert, A. Moa= yyeri, C. Libanati, C.C. Gl=C3=BCer =C2=B7 Gradients of risk of clinical risk factors for hip and vertebral fra= cture are generally larger in men than in women: results from a large healt= h insurance database. C.C. Gl=C3=BCer, K. Engelke, M. Kistler, F. Thomasius= , P. Hadji, B. Schweikert, A. Moayyeri, C. Libanati=C2=A0 =C2=B7 Inhibition/deletion of Wise (Sostdc1) potentiates cortical bone buil= ding effects of Sost deficiency. R.B. Choi, G.G. Loots, A.G. Robling (abstr= act #XX) =C2=B7 Nmp4 Underlies the Treatment Plateaus of Osteoanabolics. C. Korff, E= .G. Atkinson, D.J. Horan, M. Adaway, A.G. Robling, J.P. Bidwell=C2=A0 For further information, contact UCB:=C2=A0 Global Communications Adriaan Snauwaert T+32 497 70 23 46 [email protected] Investor Relations Antje Witte T +32 2 559 9414 [email protected]=C2=A0 About the study methodology and patient population FRAME and ARCH (Lewiecki et al.) Postmenopausal women with osteoporosis were randomized to romosozumab (ROMO= ) 210 mg monthly or comparator (FRAME: PBO; ARCH: alendronate [ALN] 70mg) f= or 12 months. After 12 months all patients received denosumab (DMAB) in FRA= ME or ALN in ARCH. For each study, data from a subset of 200 randomly selec= ted women per treatment group who had total hip DXA scans at baseline (BL),= month (M) 12, and M24 and had provided consent for future research were in= cluded in the analysis. Percentage change from BL to M12 and M24 in cortica= l volumetric BMD (CvBMD), cortical thickness (Cth), cortical surface BMD (C= sBMD), and trabecular vBMD (TvBMD) were evaluated. Percentage changes were = assessed by repeated measures model adjusting for baseline covariates. STRUCTURE (Lewiecki et al.) Postmenopausal women with osteoporosis who had received oral bisphosphonate= (BP) therapy for =E2=89=A53 years and ALN for =E2=89=A51 year prior to scr= eening were then randomized 1:1 to receive open-label ROMO or teriparatide = (TPTD) for 12M. Data from women who had total hip DXA scans at baseline (BL= ), M6, and M12 and had provided consent for future research were included i= n this analysis. Data from 308 women from STRUCTURE (ROMO, 160; TPTD, 148) = who had evaluable 3D assessments at BL, M6, and M12 were analyzed. Percenta= ge change from BL to M6 and M12 in cortical vBMD (CvBMD), cortical thicknes= s (Cth), cortical surface BMD (CsBMD), and TvBMD were evaluated. Percentage= changes were assessed by repeated measures model adjusting for BL covariat= es. About EVENITY=C2=AE=E2=96=BC (romosozumab)^8 Romosozumab is a bone-forming monoclonal antibody. It is designed to work b= y inhibiting the activity of sclerostin, which simultaneously results in in= creased bone formation and to a lesser extent decreased bone resorption. Th= e romosozumab development program includes 19 clinical studies that enrolle= d approximately 14,000 patients. EVENITY has been studied for its potential= to reduce the risk of fractures in an extensive global phase 3 program tha= t included two large fracture trials comparing romosozumab to either placeb= o or active comparator in over 11,000 postmenopausal women with osteoporosi= s. Amgen and UCB are co-developing romosozumab.=E2=96=BCThis product is sub= ject to additional monitoring. This will allow quick identification of new = safety information. Healthcare professionals are asked to report any suspec= ted adverse reactions. Important Safety Information about EVENITY^=C2=AE (romosozumab) in the EU/E= EA In the EU, Romosozumab is indicated for treatment of severe osteoporosis in= postmenopausal women at high risk of fracture. Contraindications: Romosozu= mab is contraindicated in patients who are allergic to romosozumab or any o= f the excipients, who have low levels of calcium in the blood (hypocalcaemi= a), or who have a history of myocardial infarction (heart attack) or stroke= . Myocardial infarction or stroke: Heart attack and stroke have been report= ed in patients receiving Romosozumab in randomised controlled trials (uncom= mon). Treatment with Romosozumab should not be initiated in patients with a= history of heart attack or stroke. When determining whether to use Romosoz= umab for an individual patient, the presence of risk factors for cardiovasc= ular problems, including established cardiovascular disease, high blood pre= ssure, high blood fat levels, diabetes, smoking or kidney problems, should = be evaluated. Romosozumab should only be used if the prescriber and patient= agree that the benefit outweighs the risk. If a patient experiences a myoc= ardial infarction or stroke during therapy, treatment with Romosozumab shou= ld be discontinued. Hypocalcaemia: Transient hypocalcaemia has been observe= d in patients receiving Romosozumab. Hypocalcaemia should be corrected prio= r to initiating therapy with Romosozumab and patients should be monitored f= or signs and symptoms of hypocalcaemia. If any patient presents with suspec= ted symptoms of hypocalcaemia during treatment, calcium levels should be me= asured. Patients should be adequately supplemented with calcium and vitamin= D. Patients with severe renal impairment (estimated glomerular filtration = rate [eGFR] 15 to 29ml/min/1.73m2) or receiving dialysis are at greater ris= k of developing hypocalcaemia and the safety data for these patients are li= mited. Calcium levels should be monitored in these patients. Hypersensitivi= ty: Clinically significant hypersensitivity reactions, including angioedema= , erythema multiforme, and urticaria occurred in the Romosozumab group in c= linical trials. If an anaphylactic or other clinically significant allergic= reaction occurs, appropriate therapy should be initiated and use of Romoso= zumab should be discontinued. Osteonecrosis of the Jaw: Osteonecrosis of th= e jaw (ONJ) has been reported rarely in patients receiving Romosozumab. The= following risk factors should be considered when evaluating a patient=E2= =80=99s risk of developing ONJ: (1) potency of the medicinal product that i= nhibits bone resorption (the risk increases with the antiresorptive potency= of the compound), and cumulative dose of bone resorption therapy, (2) canc= er, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking= , (3) concomitant therapies: corticosteroids, chemotherapy, angiogenesis in= hibitors, radiotherapy to head and neck, (4) poor oral hygiene, periodontal= disease, poorly fitting dentures, history of dental disease, invasive dent= al procedures e.g. tooth extractions. All patients should be encouraged to = maintain good oral hygiene and receive routine dental check-ups. Dentures s= hould fit correctly. Patients under dental treatment, or who will undergo d= ental surgery (e.g. tooth extractions) whilst being treated with Romosozuma= b should inform their doctor about their dental treatment and inform their = dentist that they are receiving Romosozumab. Patients should immediately re= port any oral symptoms such as dental mobility, pain or swelling or non-hea= ling of sores or pus discharge during treatment with Romosozumab. Patients = who are suspected of having or who develop ONJ while receiving Romosozumab = should receive care by a dentist or an oral surgeon with expertise in ONJ. = Discontinuation of Romosozumab therapy should be considered until the condi= tion resolves and contributing risk factors are mitigated where possible. A= typical Femoral Fractures: Atypical low-energy or low trauma fracture of th= e femoral shaft, which can occur spontaneously, has been reported rarely in= patients receiving Romosozumab. Any patient who presents with new or unusu= al thigh, hip, or groin pain should be suspected of having an atypical frac= ture and should be evaluated to rule out an incomplete femur fracture. Pati= ent presenting with an atypical femur fracture should also be assessed for = symptoms and signs of fracture in the contralateral limb. Interruption of R= omosozumab therapy should be considered, based on an individual benefit-ris= k assessment. Adverse Reactions: The most common adverse reactions were nas= opharyngitis (13.6%) and arthralgia (12.4%). Common adverse reactions inclu= ded hypersensitivity, sinusitis, rash, dermatitis, headache, neck pain, mus= cle spasms and injection site reactions (most frequent injection site react= ions were pain and erythema). Uncommon adverse reactions were urticaria, hy= pocalcaemia, stroke, myocardial infarction and cataract. Finally, rare side= effects were serious allergic reactions which caused swelling of the face,= throat, hands, feet, ankles or lower legs (angioedema) and acute skin erup= tion (erythema multiforme). EVENITY^=C2=AE is a registered trademark of the UCB Group of Companies.=C2= =A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With more than 8 000 people op= erating in more than 40 countries, the company generated revenue of =E2=82= =AC5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). F= ollow us on Twitter: @UCB_news About the Amgen and UCB Collaboration Since 2004, Amgen and UCB have been working together under a collaboration = and license agreement to research, develop and market antibody products tar= geting the protein sclerostin. As part of this agreement, the two companies= continue to collaborate on the development of romosozumab for the treatmen= t of osteoporosis. This gene-to-drug project demonstrates how Amgen and UCB= are joining forces to translate a genetic discovery into a new medicine, t= urning conceptual science into a reality. Forward looking statements=C2=A0 This press release contains forward-looking statements based on current pla= ns, estimates and beliefs of management. All statements, other than stateme= nts of historical fact, are statements that could be deemed forward-looking= statements, including estimates of revenues, operating margins, capital ex= penditures, cash, other financial information, expected legal, political, r= egulatory or clinical results and other such estimates and results. By thei= r nature, such forward-looking statements are not guarantees of future perf= ormance and are subject to risks, uncertainties and assumptions which could= cause actual results to differ materially from those that may be implied b= y such forward-looking statements contained in this press release. Importan= t factors that could result in such differences include: changes in general= economic, business and competitive conditions, the inability to obtain nec= essary regulatory approvals or to obtain them on acceptable terms, costs as= sociated with research and development, changes in the prospects for produc= ts in the pipeline or under development by UCB, effects of future judicial = decisions or governmental investigations, product liability claims, challen= ges to patent protection for products or product candidates, changes in law= s or regulations, exchange rate fluctuations, changes or uncertainties in t= ax laws or the administration of such laws and hiring and retention of its = employees.=C2=A0 UCB is providing this information as of the date of this press release and = expressly disclaims any duty to update any information contained in this pr= ess release, either to confirm the actual results or to report a change in = its expectations. There is no guarantee that new product candidates in the = pipeline will progress to product approval or that new indications for exis= ting products will be developed and approved. Products or potential product= s which are the subject of partnerships, joint ventures or licensing collab= orations may be subject to differences between the partners. Also, UCB or o= thers could discover safety, side effects or manufacturing problems with it= s products after they are marketed. Moreover, sales may be impacted by inte= rnational and domestic trends toward managed care and health care cost cont= ainment and the reimbursement policies imposed by third-party payers as wel= l as legislation affecting biopharmaceutical pricing and reimbursement. References 1. Lewiecki E.M., Betah D., Humbert L., Libanati C., Oates M., Shi Y., Winz= enrieth R., Ferrari S., Omura F. Cortical and trabecular bone improvements = with romosozumab followed by denosumab or alendronate assessed using 3D mod= eling from DXA images. Abstract=C2=A0 2. Lewiecki E.M., Betah D., Humbert L., Libanati C., Oates M., Shi Y., Winz= enrieth R., Ferrari S., Omura F. Comparison of romosozumab and teriparatide= effects on cortical and trabecular bone using 3D modeling from DXA images = in postmenopausal women transitioning from bisphosphonate therapy.=C2=A0 3. Cosman F., Oates M., Betah D., Ferrari S., Timoshanko J., Wang Z., McClu= ng M. One Year of Romosozumab Followed by One Year of Denosumab Compared Wi= th Two Years of Denosumab: BMD and Fracture Results From the FRAME and FRAM= E Extension Studies.=C2=A0 4. McClung M.R., Betah D., Leder B.Z., Kendler D.L., Oates M., Timoshanko J= ., Wang Z. Effect of Romosozumab on Bone Microarchitecture as Assessed by T= issue Thickness=E2=80=93Adjusted Trabecular Bone Score in Postmenopausal Wo= men with Osteoporosis: Results from the ARCH Study.=C2=A0 5. S=C3=B6zen T., =C3=96z=C4=B1=C5=9F=C4=B1k L., Ba=C5=9Faran N.=C3=87. An = overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46-56 6. Johnell O., Kanis, J.A. An estimate of the worldwide prevalence and disa= bility associated with osteoporotic fractures. Osteoporosis Int, 2006. 17(1= 2):1726-33 7. IOF SCOPE report 2021 [Online]. Available at: https://www.osteoporosis.f= oundation/sites/iofbonehealth/files/2021-06/Kanis2021_Article_SCOPE2021ANew= ScorecardForOsteo.pdf (Last accessed August 2022) 8. Evenity^=C2=AE SmPC, current version. GenericFile 220908 ASBMR 2022 data and curtain raiser press release FINAL ENG (https://= mb.cision.com/Public/18595/3626810/9f3b7a172fdc55a1.pdf) ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x115450x1x6868579x2400= 0x6&Email=3Dregnews%40symexglobal.com. UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium

Attachments

Disclaimer

UCB SA published this content on 09 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 September 2022 06:30:18 UTC.